The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early, non-randomized data suggest that SGLT-1/2 inhibitors may reduce cardiovascular events in patients with hypertrophic cardiomyopathy”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Research works printed but not linked: 4
- Maron, 2018, Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy, J Am Coll Cardiol HF, 6, 353
- Ranjbarvaziri, 2021, Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy, Circulation, 144, 1714, 10.1161/CIRCULATIONAHA.121.053575 · DOI
- Lopaschuk, 2020, Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 inhibitors, J Am Coll Cardiol Basic Trans Science, 5, 632
- Subramanian, 2023, Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy, Am J Cardiol, 188, 80, 10.1016/j.amjcard.2022.10.054 · DOI · Paper page
Cited by
Sorted by citations
Current management of hypertrophic cardiomyopathy
Sikand, N., Stendahl, J., Sen, S., Lampert, R., & Day, S. (2025) · BMJ · doi:10.1136/bmj-2023-077274 · Cited by 26
Metadata
- Authors
- Aglan, A., Fath, A. R., Eldaly, A. S., Anderson, A. S., Phillips, J. S., Maron, B. J., Maron, M. S., & Rowin, E. J.
- Venue
- JACC: Advances
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 3
- Issue
- 3
- Pages
- 100843
- ISSN
- 2772-963X
- PMC
- PMC11198447
- Cited by
- 29
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
